Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke - Pilot, Single-center, Randomized, Patient-assessor Blinded, Sham-controlled Study

NCT04266639 is registered in ClinicalTrials.gov with Grethe Andersen as lead sponsor.

NCT NCT04266639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04266639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rheo-Erythrocrine Dysfunction as a Biomarker for RIC Treatment in Acute Ischemic Stroke - Pilot, Single-center, Randomized, Patient-assessor Blinded, Sham-controlled Study
Lead sponsor
Grethe Andersen
Phase
Not applicable
Overall status
Completed
Start date
July 29, 2020
Completion date
July 31, 2021
Enrollment
45 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

central nervous system diseases, cerebrovascular disorders, ischemic stroke, stroke, acute